[Immunosuppressive therapy update 2010 for ANCA-associated glomerulonephritis and intractable nephrotic syndrome].
Yoshida
Masaharu
M
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015122:Mercaptopurine / Q000008:administration & dosage / Q000031:analogs & derivatives; D008775:Methylprednisolone / Q000008:administration & dosage; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000276:immunology*; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D016559:Tacrolimus / Q000008:administration & dosage
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; C488629:azathiopurine; D000069283:Rituximab; D016572:Cyclosporine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D016559:Tacrolimus; D008775:Methylprednisolone